AU
CA
NZ
UK
US
IND
Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Phibro Animal Health Corp (PAHC) Q3 2025 Earnings Call Highlights: Robust Sales Growth and ...
Fri 09 May 25, 07:25 AMHaemonetics (HAE) Earnings Expected to Grow: Should You Buy?
Thu 01 May 25, 02:01 PMPAHC or BSX: Which Is the Better Value Stock Right Now?
Wed 16 Apr 25, 03:40 PMTop 3 MedTech Stocks to Weather the Trump Tariff Turbulence
Wed 09 Apr 25, 12:57 PM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | 54.07M | 72.30M | 66.50M | 55.50M | 71.50M |
| Minority interest | - | - | - | - | - |
| Net income | 32.61M | 49.20M | 54.40M | 33.60M | 54.70M |
| Selling general administrative | 226.39M | 206.41M | 196.51M | 187.69M | 181.40M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 298.24M | 285.40M | 271.40M | 256.90M | 264.60M |
| Reconciled depreciation | 34.01M | 32.70M | 31.89M | 32.34M | 27.56M |
| Ebit | 74.47M | 46.30M | 43.02M | 36.86M | 55.84M |
| Ebitda | 108.49M | 79.00M | 74.90M | 69.20M | 83.40M |
| Depreciation and amortization | 34.01M | 32.70M | 31.89M | 32.34M | 27.56M |
| Non operating income net other | -2.45500M | 5.22M | 4.48M | -0.82600M | 0.06M |
| Operating income | 71.85M | 46.30M | 43.02M | 36.86M | 73.30M |
| Other operating expenses | 906.04M | 863.30M | 758.50M | 731.20M | 744.80M |
| Interest expense | 17.95M | 11.90M | 12.90M | 12.90M | 11.80M |
| Tax provision | 21.46M | 23.15M | 12.08M | 21.96M | 16.79M |
| Interest income | 3.35M | 0.82M | 0.84M | 1.76M | 1.90M |
| Net interest income | -15.32100M | -11.87500M | -12.88000M | -12.85600M | -11.77600M |
| Extraordinary items | - | - | - | - | 0.36M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 21.46M | 23.20M | 12.10M | 22.00M | 16.80M |
| Total revenue | 977.89M | 942.30M | 833.40M | 800.40M | 828.00M |
| Total operating expenses | 226.39M | 206.40M | 196.50M | 187.70M | 181.40M |
| Cost of revenue | 679.65M | 656.90M | 562.00M | 543.50M | 563.40M |
| Total other income expense net | -2.45500M | 26.00M | 23.48M | 18.64M | 15.66M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 32.61M | 49.17M | 54.38M | 33.55M | 54.71M |
| Net income applicable to common shares | 32.61M | 49.17M | 54.38M | 33.55M | 54.71M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 971.40M | 931.70M | 841.33M | 784.10M | 726.67M |
| Intangible assets | 54.99M | 63.86M | 62.28M | 71.00M | 47.48M |
| Earning assets | - | - | - | - | - |
| Other current assets | 63.39M | 49.29M | 42.53M | 37.31M | 27.25M |
| Total liab | 688.89M | 669.26M | 602.80M | 595.90M | 510.66M |
| Total stockholder equity | 282.51M | 262.44M | 238.53M | 188.20M | 216.01M |
| Deferred long term liab | 1.41M | 1.44M | 1.81M | 1.02M | 1.53M |
| Other current liab | 18.86M | 74.19M | 20.84M | 21.18M | 15.65M |
| Common stock | 0.00400M | 0.00400M | 0.00400M | 0.00400M | 0.00400M |
| Capital stock | 0.00400M | 0.00400M | 0.00400M | 0.00400M | 0.00400M |
| Retained earnings | 260.91M | 247.75M | 218.01M | 183.06M | 168.93M |
| Other liab | 31.27M | 28.99M | 27.97M | 46.73M | 42.79M |
| Good will | 53.27M | 53.23M | 52.68M | 52.68M | 27.35M |
| Other assets | 30.83M | 27.98M | 35.65M | 33.39M | 41.25M |
| Cash | 41.28M | 74.25M | 50.21M | 36.34M | 57.57M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 176.00M | 190.83M | 164.12M | 157.24M | 154.23M |
| Current deferred revenue | 54.94M | - | 58.92M | 44.78M | 52.84M |
| Net debt | 468.69M | 396.24M | 376.49M | 374.38M | 268.60M |
| Short term debt | 28.35M | 21.05M | 15.99M | 25.19M | 12.54M |
| Short long term debt | 22.30M | 15.00M | 9.38M | 18.75M | 12.54M |
| Short long term debt total | 509.97M | 470.48M | 426.71M | 410.72M | 326.18M |
| Other stockholder equity | 135.80M | 135.80M | 135.80M | 135.53M | 133.27M |
| Property plant equipment | 195.57M | 165.49M | 187.67M | 170.98M | 140.24M |
| Total current assets | 585.72M | 566.23M | 498.91M | 451.84M | 466.16M |
| Long term investments | 11.09M | 10.35M | 10.11M | 10.02M | 9.63M |
| Net tangible assets | 174.25M | 145.35M | 123.57M | 64.53M | 141.19M |
| Short term investments | 40.00M | 17.00M | 43.00M | 55.00M | 24.00M |
| Net receivables | 163.48M | 166.54M | 146.85M | 126.52M | 159.02M |
| Long term debt | 452.54M | 417.93M | 382.71M | 368.26M | 96.00M |
| Inventory | 277.57M | 259.16M | 216.31M | 196.66M | 198.32M |
| Accounts payable | 73.85M | 95.60M | 68.36M | 66.09M | 73.19M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -114.21000M | -121.11300M | -115.29300M | -130.38500M | -86.18100M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.00400M | 0.00400M | 0.00400M | 0.00400M | 0.00400M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 260.91M | 247.75M | 218.01M | 183.06M | 168.93M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 26.28M | 29.02M | 19.82M | 16.16M | 12.03M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 385.67M | 365.47M | 342.42M | 332.26M | 260.51M |
| Capital lease obligations | 35.13M | 37.56M | 34.62M | 23.71M | - |
| Long term debt total | 452.54M | 417.93M | - | - | 217.63M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -23.00000M | 27.35M | 12.00M | -31.00000M | 26.00M |
| Change to liabilities | -28.57700M | 29.51M | 3.18M | -16.18100M | 16.19M |
| Total cashflows from investing activities | -74.01800M | -22.58200M | -18.58000M | -120.39000M | -14.13300M |
| Net borrowings | 41.21M | 50.00M | 5.38M | 60.35M | 13.35M |
| Total cash from financing activities | 26.99M | 16.34M | -16.99500M | 40.94M | -4.10700M |
| Change to operating activities | -12.41600M | -0.37300M | -2.33800M | -21.76700M | -3.37400M |
| Net income | 32.61M | 49.17M | 54.38M | 33.55M | 54.71M |
| Change in cash | -32.96700M | 24.04M | 13.87M | -21.23000M | 28.41M |
| Begin period cash flow | 74.25M | 50.21M | 36.34M | 57.57M | 29.17M |
| End period cash flow | 41.28M | 74.25M | 50.21M | 36.34M | 57.57M |
| Total cash from operating activities | 13.31M | 31.65M | 48.31M | 59.35M | 47.17M |
| Issuance of capital stock | - | - | 0.00000M | 0.00000M | 1.13M |
| Depreciation | 34.01M | 32.70M | 31.89M | 32.34M | 27.56M |
| Other cashflows from investing activities | 0.78M | -12.89100M | -1.26000M | -55.34500M | -10.24200M |
| Dividends paid | 19.44M | 19.44M | 19.43M | 19.42M | 18.59M |
| Change to inventory | -11.22200M | -46.99900M | -12.49800M | -12.93000M | -20.98200M |
| Change to account receivables | 5.33M | -23.62500M | -18.20900M | 28.71M | -23.67900M |
| Sale purchase of stock | - | - | - | - | 1.13M |
| Other cashflows from financing activities | 329.74M | 292.16M | 614.56M | 243.00M | 216.78M |
| Change to netincome | -12.90200M | -6.49800M | -8.92800M | 8.66M | -0.04700M |
| Capital expenditures | 51.79M | 37.04M | 29.32M | 34.05M | 29.89M |
| Change receivables | 5.33M | -23.62500M | -18.20900M | 28.71M | -23.67900M |
| Cash flows other operating | -6.66900M | -3.20900M | -3.52900M | -15.69100M | -7.47200M |
| Exchange rate changes | - | - | 1.14M | -1.12400M | -0.52400M |
| Cash and cash equivalents changes | -33.72100M | 25.41M | 13.87M | -21.23000M | 28.41M |
| Change in working capital | -41.13300M | -44.63900M | -29.86900M | -13.65600M | -35.94300M |
| Stock based compensation | -10.39800M | 0.00000M | 1.13M | 2.26M | 2.26M |
| Other non cash items | 1.06M | -4.78600M | -7.04100M | -3.27300M | -1.31900M |
| Free cash flow | -38.48400M | -5.39500M | 18.99M | 25.30M | 17.28M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PAHC Phibro Animal Health Corporation |
1.65 3.38% | 50.43 | 56.38 | 10.57 | 0.54 | 1.96 | 0.97 | 11.37 |
| ZTS Zoetis Inc |
-1.87 1.53% | 120.49 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
0.56 2.23% | 25.64 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-2.64 2.02% | 128.01 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.14 0.77% | 18.21 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, industrial, environmental, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Glenpointe Centre East, Teaneck, NJ, United States, 07666-6712
| Name | Title | Year Born |
|---|---|---|
| Mr. Jack Clifford Bendheim | Chairman, Pres & CEO | 1947 |
| Mr. Damian Finio | Chief Financial Officer | 1970 |
| Mr. Larry L. Miller | Chief Operating Officer | 1964 |
| Mr. Daniel M. Bendheim | Exec. VP of Corp. Strategy & Director | 1972 |
| Mr. Rob Aukerman | Pres of North America Region | 1958 |
| Mr. Thomas G. Dagger | Sr. VP, Gen. Counsel & Corp. Sec. | 1958 |
| Ms. Lisa A. Escudero | Sr. VP of HR | 1962 |
| Mr. Jonathan Bendheim | Pres of MACIE Region, GM of Israel Operations & Director | 1976 |
| Mr. Ramon Fuenmayor | Pres South America Region | NA |
| Mr. Jean Christophe Filippi | Pres of Asia Pacific Region | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...